Click here to view the printer friendly version of this press release
ALBUQUERQUE, NM --- Manhattan Scientifics (OTC BB: MHTX) is pleased to post an article from the New Mexico Business Weekly describing the early cancer detection work of Dr. Edward R. Flynn.
Read the article on the Manhattan Scientifics' website by linking to http://www.mhtx.com/dr-edward-flynn.htm
The article describes how “Flynn is drawing on his experience as a nuclear physicist to develop new, ground-breaking technology that can detect breast and ovarian cancers much earlier than current diagnostic techniques. His work also has produced an innovative method to more accurately determine if leukemia patients are benefiting from chemotherapy treatments. Flynn’s technology is based on magnetic nano particles injected into the body. The particles carry antibodies that bind with cancer cells to pinpoint the exact location of diseases, both for diagnostics and for targeted therapies.”
Dr. Flynn’s research has been funded by Small Business Innovative Research Grants from the National Institutes of Health. Senior Scientific collaborates with the University of New Mexico Health Sciences Center. Dr. Flynn state, “I am confident that by partnering with Manhattan Scientifics now, our team will achieve the ultimate goals of the program.”
On October 20, 2009, Manhattan Scientifics and Dr. Flynn signed an initial Letter of Intent describing their intention to cooperate to commercializing products and technologies arising out of Dr. Flynn's work. The parties are finalizing a definitive agreement to move forward together.